Clinical Trial Update: Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating nimotuzumab in combination with a TGP regimen as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• TGP regimen (TGP)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Nasopharyngeal Carcinoma by AJCC V8 Stage | Phase 2 | Status: RECRUITING